| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
related myeloid neoplasms (t-MN) occur due to direct mutational events
of chemotherapeutic agents and radiotherapy. Disease latency,
mutational events and prognosis vary with drugs categories.
Allogeneic Stem Cell Transplantation for t-MN
|Table 1. Results of the review: outcomes of patients with therapy-related AML/MDS submitted to HSCT.|
Monocentric Observational Study
|Table 2. Detailed report of patients, primary and therapy-related disease and treatment.|
|Table 3. Transplant for t-MN: features and outcomes.|
Figure 1. Five-years outcomes of therapy-related AML/MDS after HSCT: 1A) Kaplan Meier for DFS; 1B) Kaplan Meier for OS; 1C) cumulative incidence of NRM; 1D) cumulative incidence of RRD; 1E) Kaplan Meier for OS according to cGvHD development; 1F) Kaplan Meier for OS according to relapse occurrence; 1G) cumulative incidence of NRM according to transplant conditioning regimen; 1H) cumulative incidence of RRD according to cGvHD development.